Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -2.86% | -2.86% | +9.68% |
Financials (USD)
Sales 2024 * | 103M | Sales 2025 * | 76.06M | Capitalization | 132M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.28 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
-12
x | P/E ratio 2025 * |
-3.6
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -2.86% | ||
1 week | -2.86% | ||
1 month | +4.29% | ||
3 months | -30.61% | ||
6 months | +22.30% | ||
Current year | +9.68% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.7 | -2.86% | 953,744 |
24-05-30 | 1.75 | -.--% | 1,651,680 |
24-05-29 | 1.75 | -2.23% | 2,788,394 |
24-05-28 | 1.79 | +2.29% | 2,243,648 |
24-05-24 | 1.75 | -4.37% | 1,074,056 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.68% | 132M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CTMX Stock